Novel titanocene anti-cancer drugs derived from fulvenes and titanium dichloride |
| |
| Authors: | Matthias Tacke Lorcan T. Allen William M. Gallagher Oscar Mendoza Franz-Josef K. Rehmann |
| |
| Affiliation: | a Chemistry Department, Conway Institute of Biomolecular and Biomedical Research, Centre for Synthesis and Chemical Biology (CSCB), University College Dublin, Belfield, Dublin 4, Ireland
b Pharmacology Department, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland |
| |
| Abstract: | Starting from 6-(p−N,N-dimethylanilinyl)fulvene (1a) or 6-(pentamethylphenyl)fulvene (1b) [1,2-di(cyclopentadienyl)-1,2-di(p−N,N-dimethylaminophenyl)ethanediyl] titanium dichloride (2a) and [1,2-di(cyclopentadienyl)-1,2-bis(pentamethylphenyl)ethanediyl] titanium dichloride (2b) and their corresponding dithiocyanato complexes (3a, 3b) were synthesized. Titanocene 2b did not show a cytotoxic effect, but when 2a was tested against pig kidney carcinoma cells (LLC-PK) or human ovarian carcinoma cells (A2780/cp70) inhibitory concentrations (IC50) of 2.7 × 10−4 and 1.9 × 10−4 M, respectively, were observed. |
| |
| Keywords: | Anti-cancer drug cis-Platinum Titanocene Fulvene LLC-PK A2780/cp70 |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
